Lilly, Bristol-Myers approved to market wider Erbitux use
Eli Lilly and Co. and Bristol-Myers Squibb Co. won U.S. approval to expand marketing of the cancer drug Erbitux for late-stage head and neck tumors.
Eli Lilly and Co.
Articles
Drug shortages hit Lilly, Endocyte
The nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co. and Endocyte Inc.
Lilly hid Zyprexa’s diabetes risks, family’s lawyer argues
Eli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award the family $40 million in compensatory damages.
Lilly loses British Supreme Court ruling over gene patent
The British Supreme Court ruled in favor of Human Genome Sciences Inc. in its dispute with Eli Lilly and Co. over the validity of a patent for a gene sequence that could be used to treat people with immune diseases.
Q&A
As an Eli Lilly and Co. lobbyist in Washington, D.C., Jay Bonitt is hoping the Congressional “super committee” charged with trimming the federal budget doesn’t turn to the Medicare prescription drug program, known as Part D, to do so. Bonitt, Lilly's vice president of federal affairs, said the program is under budget and helps spur drugmakers to further innovation.
Lilly wins European approval for new use of Alimta
Indianapolis-based drugmaker can now market lung cancer drug as a continuation maintenance therapy, potentially boosting sales after recent loss of patent on bestseller Zyprexa.
Zyprexa era comes to an end for Lilly
On Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller, ending 15 years of highly lucrative sales.
Lilly fights view that fate hinges on Alzheimer’s drug
Analysts have eyes on trial data for drug that could be a game-changer for the company.
FDA approves first generic versions of Zyprexa
Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, which posted sales of $5.7 billion last year for Indianapolis-based drugmaker Eli Lilly and Co Inc.
Lilly: Vendors key after Zyprexa patent loss
Lilly’s patent-loss challenges—the biggest of which takes effect today—will force the company to rely even more on its 1,300 Indiana vendors.
Profit falls at Lilly but meets Wall Street expectations
The Indianapolis-based drugmaker earned $1.24 billion in the three months ended Sept. 30, down 5 percent from the same quarter a year ago, even as revenue surged 9 percent.
Lilly diabetes drug wins approval for expanded use
Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s Byetta has received expanded approval for use with the world’s top-selling insulin to treat Type 2 diabetes.
Lilly announces replacements for two retiring executives
Bryce Carmine, president of Lilly’s bio-medicines division, and Frank Deane, president of Lilly’s global manufacturing operations, both will retire on Dec. 31.
Lilly gets dinged for job cuts
Eli Lilly and Co. got called out in a recent report on companies that took advantage of the 2004 tax holiday on foreign profits and have since slashed jobs.
FDA approves Cialis for enlarged prostate
Cialis, Lilly’s blockbuster erectile dysfunction drug, now can be taken to treat enlarged prostate. FDA approval means men who suffer from both disorders can take one medication.
Lilly slashes water use, reduces waste output
By 2013, Lilly hopes to reduce water intake another 5 percent, while reducing the amount of waste sent to landfills an additional 20 percent.
Lilly CEO says he’s not interested in Pfizer animal unit
Drugmaker Eli Lilly and Co. doesn’t plan to buy Pfizer Inc.’s $3.58 billion animal-health business, CEO John Lechleiter said Wednesday.
Eli Lilly, Turkish firm in talks to sell drugs in 26 nations
Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, is in talks with Mustafa Nevzat Ilac Sanayii AS to sell the Turkish company’s treatments in 26 countries, said Mustafa Nevzat’s CEO.
Lilly’s Alimta get favorable opinion for new use in Europe
If approved for continuation maintenance, Eli Lilly and Co.’s Alimta could be used for longer stretches in lung cancer patients, generating more revenue.
Debate rages over whether Lilly’s Byetta lifts cancer risk
A German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.